Aia Group LTD Glaukos Corp Transaction History

Aia Group LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$40.27 - $56.99 $908,974 - $1.29 Million	-22,572 Closed	0 $0
Q3 2021 Nov 05, 2021	BUY	$47.43 - $84.23 $255,268 - $453,325	5,382 Added 31.31%	22,572 $1.09 Million
Q2 2021 Aug 03, 2021	BUY	$73.06 - $97.7 $95,197 - $127,303	1,303 Added 8.2%	17,190 $968,000
Q1 2021 May 14, 2021	BUY	$70.43 - $97.42 $401,169 - $554,904	5,696 Added 55.89%	15,887 $1.33 Million
Q4 2020 Feb 12, 2021	BUY	$48.9 - $75.26 $498,339 - $766,974	10,191 New	10,191 $944,000

342

46.8M

132K

188K

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $7.45B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

Get notified when there are updates to the investment portfolio of Aia Group LTD, based on Form 13F filings with the SEC.

Stay updated on Aia Group LTD with notifications on news.